Old drug fluvoxamine, new hope for COVID-19
26th treatment shown to reduce risk in
November 2021 *, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
|
Review of research supporting the use of fluvoxamine for COVID-19. Authors note the favorable safety profiles, widespread availability, very low cost, and oral administration.
Hashimoto et al., 2 Sep 2021, peer-reviewed, 3 authors.
Abstract: European Archives of Psychiatry and Clinical Neuroscience
https://doi.org/10.1007/s00406-021-01326-z
LETTER TO THE EDITOR
Old drug fluvoxamine, new hope for COVID‑19
Yaeko Hashimoto1,2 · Takuji Suzuki1 · Kenji Hashimoto2
Received: 24 August 2021 / Accepted: 27 August 2021
© Springer-Verlag GmbH Germany, part of Springer Nature 2021
The coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by the novel coronavirus SARSCoV-2. Despite the second vaccination for SARS-CoV-2,
the number of individuals infected with SARS-CoV-2 variants (i.e., delta and lambda) has markedly increased worldwide. Although approximately 80% of individuals infected
with SARS-CoV-2 is mild to moderate, a part of them may
convert to severe clinical stages in about 1 week, ultimately
resulting in the intubation or death. Using drug repurposing,
it is, therefore, necessary to discover drugs that can prevent
clinical deterioration [1]. Here, we discuss the emergent use
of the old antidepressant fluvoxamine which may block clinical deterioration in mild to moderate patients infected with
SARS-CoV-2.
In November 2020, Dr. Lenze and his colleagues reported
that fluvoxamine could prevent clinical deterioration in adult
outpatients infected with SARS-CoV-2. In the study, clinical
deterioration occurred in 0 of the fluvoxamine group (n = 80)
and in 6 of placebo group (n = 72) [2]. Although sample
size of this study was small, this study strongly encouraged further trials using a large sample size. In February
2021, Dr. Seftel and his colleague reported a prospective,
non-randomized observational cohort study of fluvoxamine
in outpatients (n = 113) infected with SARS-CoV-2 at the
Golden Gate Fields horse racing track in Berkeley, California [3]. Incidence of hospitalization was 0 of the fluvoxamine-treated group (n = 65) and 6 of the observation alone
group (n = 48). Two patients required intensive care unit stay
with mechanical ventilation, one of them died. On April 23,
2021, fluvoxamine was added in the US National Institutes
of Health (NIH) COVID-19 Guidelines Panel although there
is insufficient evidence for the efficacy of fluvoxamine.
* Kenji Hashimoto
hashimoto@faculty.chiba-u.jp
1
Department of Respirology, Chiba University Graduate
School of Medicine, Chiba 260‑8670, Japan
2
Division of Clinical Neuroscience, Chiba University Center
for Forensic Mental Health, 1‑8‑1 Inohana, Chiba 260‑8670,
Japan
On August 6, 2021, the interim results of TOGETHER
trial (NCT04727424) by a multinational group in Canada
and Brazil were presented at the NIH symposium. They
compared three compounds, fluvoxamine, the antidiabetic
drug metformin, and the antiparasitic drug ivermectin.
Although metformin and ivermectin did not show beneficial
effects, fluvoxamine was much more promising. Among the
randomized participants (n = 1,480), fluvoxamine significantly reduced the risk of disease progression by 29% (95%
confidence interval 0.54–0.93) [4].
Detailed mechanisms of action of fluvoxamine for
COVID-19 are currently unknown. In 1996, we reported
that fluvoxamine binds to endoplasmic reticulum (ER) protein sigma-1 receptor with high affinity, suggesting a role of
sigma-1 receptor in the mechanisms of its action [5]. Subsequent studies suggest that fluvoxamine is a potent agonist
at sigma-1 receptor which plays a key role in inflammation
[1, 5, 6]. Among the antidepressants, fluvoxamine was the
most potent at sigma-1 receptor [1, 5, 6]. Furthermore, fluvoxamine has..
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit